When our body fights an infection, the immune system must quickly activate defenses and trigger a beneficial inflammatory ...

CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced ...

PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...

Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.

A common cold can feel like a small thing until it is not. One day you feel fine, and the next you wake up congested, drained ...

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work ...

Interferon therapies are well established as treatment options for some types of cancer, but they have not been used to treat cancers characterized by the overproduction of blood cells. The FDA has ...

Who knows why different people have different symptoms with the common cold? Well, a new study used laboratory-grown noses ...

Treatment of COVID-19 with interferon beta-1b — even for just a few days, a much shorter period than is commonly used for maintenance in multiple sclerosis (MS), for example — is associated with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The possible FDA approval of a drug targeting the ...

Researchers grew nasal tissue in a lab to unlock clues about how your body battles the common cold.

A new study shows that the body’s early immune response, not the virus itself, often determines how severe a rhinovirus cold ...